BPH Energy wins drug patent
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Wednesday, 11 April, 2012 - 14:33
North Perth-based BPH Energy, which has links to several Western Australian medical research organisations, has announced its drug discovery spin-out Molecular Discovery Systems has been granted a patent for a gene with tumour-suppressing potential.
MDS has exclusive rights to the HLS5 gene which ASX-listed BPH said has been given a high priority for research by organisations including the Cancer Council of WA, the Medical Research Foundation of Royal Perth Hospital and the Scott Kirkbride Melanoma Research Centre.
MDS is working with the WA Institute for Medical Research to further research HLS5.